Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...
Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...
Researchers set out to determine whether microglial activation, which can trigger neuroinflammation, is associated with neuropsychiatric symptoms that often accompany Alzheimer-associated dementias,...
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
Findings from 2 trials that compared various doses of the atypical antipsychotic brexpiprazole with placebo have indicated that the drug may have additional benefits for patients with agitation due to...
Researchers recently compared the effects of treatment with an atypical antipsychotic vs placebo for various periods of time among patients with Alzheimer disease psychosis.
